1-3 of 3
R. Hehlmann, MD
Close
Sort by
Journal Articles

Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.

Andreas Hochhaus, MD, A. Neubauer, MD, M.C. Mueller, MD, T. Fischer, MD, C. Waller, MD, T.H. Bruemmendorf, MD, T. Bostel, C. Lengerke, MD, R. Hehlmann, MD, A. Burchert, MD
Journal: Blood
Blood (2007) 110 (11): 1027.
https://doi.org/10.1182/blood.V110.11.1027.1027
Published: 2007
Journal Articles

Long Term Observation of CML Patients after Imatinib Resistance Associated with BCR-ABL Mutations.

Andreas Hochhaus, MD, T. Ernst, MD, P. Erben, MD, M. C. Mueller, MD, M. Emig, MD, S. Kreil, MD, P. La Rosée, MD, T. Lahaye, MD, M. Schatz, MD, O. G. Ottmann, MD, S. Schnittger, PhD, U. Berger, MD, R. Hehlmann, MD
Journal: Blood
Blood (2005) 106 (11): 1086.
https://doi.org/10.1182/blood.V106.11.1086.1086
Published: 2005
Journal Articles

Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial.

Martin C. Mueller, MD, P. Paschka, MD, T. Lahaye, MD, Ch. Lorentz, MD, N. Gattermann, MD, D. Niederwieser, MD, G. Ehninger, MD, St Fruehauf, MD, A. Neubauer, MD, Th. Fischer, MD, B. Schultheis, MD, S. Kreil, MD, U. Haus, PhD, R. Hehlmann, MD, A. Hochhaus, MD, the German CML Study Group
Journal: Blood
Blood (2004) 104 (11): 1003.
https://doi.org/10.1182/blood.V104.11.1003.1003
Published: 2004